PROSPECTO: INFORMATION FOR THE USER

Rivastigmina Kern Pharma 1.5 mg hard capsules EFG

Rivastigmina Kern Pharma 3.0 mg hard capsules EFG

Rivastigmina Kern Pharma 4.5 mg hard capsules EFG

Rivastigmina Kern Pharma 6.0 mg hard capsules EFG

Read this prospectus carefully before starting to take the medicine, as it contains important information for you.

• Keep this prospectus, as you may need to read it again.
• If you have any doubts, consult your doctor or pharmacist.
• This medicine has been prescribed only for you and should not be given to other people, even if they have the same symptoms as you, as it may harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospectus. See section 4.

1. What is Rivastigmina Kern Pharma hard capsules and what is it used for

2. What you need to know before starting to take Rivastigmina Kern Pharma hard capsules

3. How to take Rivastigmina Kern Pharma hard capsules

4. Possible adverse effects

5. Storage of Rivastigmina Kern Pharma hard capsules

6. Contents of the package and additional information

Rivastigmina belongs to a group of substances known as cholinesterase inhibitors.

In patients with Alzheimer's disease or Parkinson's disease-associated dementia, certain nerve cells die in the brain, resulting in low levels of acetylcholine neurotransmitters (a substance that allows nerve cells to communicate with each other). Rivastigmina acts by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Rivastigmina allows for an increase in acetylcholine in the brain, helping to reduce the symptoms of Alzheimer's disease and dementia associated with Parkinson's disease.

Rivastigmina is used for the treatment of adult patients with mild to moderately severe Alzheimer's disease, a progressive brain disorder that gradually affects memory, intellectual capacity, and behavior. The capsules and oral solution can also be used for the treatment of dementia in adult patients with Parkinson's disease.

Do not take Rivastigmina Kern Pharma hard capsules

• if you are allergic (hypersensitive) to rivastigmina or to any of the other ingredients of this medicine (listed in section 6).
• if you have a skin reaction that extends beyond the size of the patch, if there is a more intense local reaction (such as blisters, increasing skin inflammation, swelling) and if there is no improvement within 48 hours after removing the transdermal patch.

If you are in any of these situations, inform your doctor and do not take Rivastigmina.

Warnings and precautions

Consult your doctor before takingRivastigmina Kern Pharma:

• if you have or have had any irregular or slow heart rhythm.
• if you have or have had any active stomach ulcer.
• if you have or have had any difficulty urinating.
• if you have or have had any seizures.
• if you have or have had any severe respiratory disease.
• if you have or have had any kidney function deterioration.
• if you have or have had any liver function deterioration.
• if you suffer from tremors.
• if you have a low body weight.
• if you have gastrointestinal reactions such as nausea, vomiting, and diarrhea. You may become dehydrated (loss of a large amount of fluid) if vomiting or diarrhea are prolonged.

If you are in any of these situations, your doctor may consider the need for closer monitoring while you are on treatment.

If you have not taken Rivastigmina for more than three days, do not take the next dose until you have consulted your doctor.

Children and adolescents

Rivastigmina should not be used in the pediatric population for the treatment of Alzheimer's disease.

Other medicines and Rivastigmina

Inform your doctor or pharmacist if you are using or have recently taken or may need to take any other medicine.

Rivastigmina should not be administered at the same time as other medicines with similar effects to Rivastigmina. Rivastigmina may interfere with anticholinergic medicines (used to relieve muscle cramps or spasms, for the treatment of Parkinson's disease, or to prevent travel sickness).

Rivastigmina should not be administered at the same time as metoclopramide (a medicine used to relieve or prevent nausea and vomiting). Taking the two medicines together may cause problems such as stiffness in the limbs and hand tremors.

If you need to undergo surgery while taking Rivastigmina, inform your doctor before any anesthetic is administered, as Rivastigmina may enhance the effects of some muscle relaxants during anesthesia.

Care should be taken when Rivastigmina is used with beta blockers (medicines such as atenolol used to treat hypertension, angina, and other heart conditions). Taking the two medicines together may cause complications such as a decrease in heart rate (bradycardia) that may lead to fainting or loss of consciousness.

Pregnancy, lactation, and fertility

If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine.

If you are pregnant, it is necessary to evaluate the benefits of using Rivastigmina against the possible adverse effects on the fetus. Rivastigmina should not be used during pregnancy unless it is clearly necessary.

You should not breastfeed during treatment with Rivastigmina.

Driving and operating machinery

Your doctor will inform you if your condition allows you to drive or use machinery safely. Rivastigmina may cause dizziness and somnolence, mainly at the start of treatment or when increasing the dose. If you feel dizzy or drowsy, do not drive, use machinery, or perform other tasks that require your attention.

Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist.

Starting Treatment

Your doctor will tell you what dose of rivastigmine you should take.

• Normally, treatment starts with a low dose.
• Your doctor will gradually increase the dose depending on how you respond to the treatment.
• The highest dose you should take is 6.0 mg twice a day.

Your doctor will regularly check if the medication is working for you. Your doctor will also monitor your weight while you are taking this medication.

If you have not taken rivastigmine for more than three days, do not take the next dose until you have consulted your doctor.

Taking This Medication

• Inform your caregiver that you are taking rivastigmine.
• To benefit from your medication, take it every day.
• Take rivastigmine twice a day (in the morning and at night), with meals.
• Swallow the capsule whole with liquid.
• Do not open or crush the capsule.

If You Take More Rivastigmina Kern Pharma Hard Capsules Than You Should

Inform your doctor if you accidentally take a dose higher than indicated. You may require medical attention. Some people who have taken accidental higher doses have experienced dizziness (nausea), vomiting, diarrhea, high blood pressure, hallucinations. A slowing of heart rate and fainting may also occur.

If You Forget to Take Rivastigmina Kern Pharma Hard Capsules

If you forget your rivastigmine dose, wait and take the next dose at the usual time. Do not take a double dose to make up for the missed doses.

If you have any other questions about using this medication, ask your doctor or pharmacist.

Like all medicines, Rivastigmina Kern Pharma hard capsules may cause side effects, although not everyone will experience them.

You may experience side effects more frequently when you start treatment or when your dose is increased.Side effects usually disappear gradually as your body gets used to the medicine.

The frequencies of side effects are:

Very common:(affect more than 1 in 10 patients)

Common:(affect between 1 and 10 in 100 patients)

Uncommon:(affect between 1 and 10 in 1,000 patients)

Rare:(affect between 1 and 10 in 10,000 patients)

Very rare:(affect less than 1 in 10,000 patients)

Frequency not known (cannot be estimated from available data):

Patients with Parkinson's disease-associated dementia experience some side effects more frequently, as well as additional side effects:

Other side effects observed with Rivastigmina transdermal patches and may appear with hard capsules:

If these symptoms occur, contact your doctor as it may require medical assistance.

Reporting side effects

If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.

Keep out of sight and reach of children.

Do not use this medicine after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.

Do not store above30°C.

Medicines should not be disposed of through drains or in the trash. Dispose of packaging and medicines you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medicines you no longer need. By doing so, you will help protect the environment.

Rivastigmina Kern Pharma Hard Capsules Composition

• The active ingredient is rivastigmine hydrogen tartrate
• The other components are: hypromellose, anhydrous colloidal silica, microcrystalline cellulose, magnesium stearate, gelatin, sodium lauryl sulfate, titanium dioxide (E171), yellow iron oxide (E172), and purified water.

Each hard capsule of Rivastigmina Kern Pharma 1.5 mg contains the equivalent of 1.5 mg of rivastigmine as rivastigmine hydrogen tartrate.

Each hard capsule of Rivastigmina Kern Pharma 3.0 mg contains the equivalent of 3.0 mg of rivastigmine as rivastigmine hydrogen tartrate.

Each hard capsule of Rivastigmina Kern Pharma 4.5 mg contains the equivalent of 4.5 mg of rivastigmine as rivastigmine hydrogen tartrate.

Each hard capsule of Rivastigmina Kern Pharma 6.0 mg contains the equivalent of 6.0 mg of rivastigmine as rivastigmine hydrogen tartrate.

Product Appearance and Packaging Contents

• Rivastigmina Kern Pharma 1.5 mg hard capsules contain a white to slightly yellowish powder in a yellow-colored capsule with a red printed mark "R 1.5" on the body.

• Rivastigmina Kern Pharma 3 mg hard capsules contain a white to slightly yellowish powder in a orange-colored capsule with a red printed mark "R 3.0" on the body.
• Rivastigmina Kern Pharma 4.5 mg hard capsules contain a white to slightly yellowish powder in a red-colored capsule with a white printed mark "R 4.5" on the body.
• Rivastigmina Kern Pharma 6 mg hard capsules contain a white to slightly yellowish powder in an orange-colored capsule with a red printed mark "R 6.0" on the body.

It is packaged in blisters and is available in three different presentations (28, 56, and 112 capsules).

Only some package sizes may be commercially available.

Marketing Authorization Holder and Responsible Manufacturer

Kern Pharma, S.L.

Venus,72- Pol. Ind.Colón II

08228 Terrassa -Barcelona

Spain

This leaflet was approved in: December 2024

“Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/”